Current advancements in wet AMD are not enough
AMD in particular impacts as many as 11 million Americans. About 15% of those affected have neovascular or wet AMD. It’s a devastating disease that can lead to irreversible vision loss.
Nancy Lurker
As President and Chief Executive Officer and Board Director, Nancy Lurker leads EyePoint Pharmaceuticals in its mission to improve the lives of people facing serious eye disorders. During her more than 30 years in the pharmaceutical industry, Nancy has driven scientific and commercial innovation working with both public and private companies from start-ups to the Fortune 500 to bring innovative therapies and diagnostic solutions to patients. She has a proven track record of maximizing the potential of new therapies and successfully implementing innovative US and global drug launches in a diversity of therapy areas. Nancy has served on numerous Boards across public and private companies, and advocacy organizations. Dedicating her career to maximizing the potential of science to improve the lives of patients, Nancy is passionate about supporting the future of STEM and engaging with the critical thinkers and innovators of tomorrow.